As the pressure to reduce costs while maintaining quality for the production intensifies Do not miss this opportunity to an insider perspective on how they gain a greater involvement of the FDA in China react.. From your colleagues to hear firsthand how the latest round of decisions IP Litigation and the passing of the new health care reform are both challenges and opportunities for the generic industry. Assess how the industry, to explore more creative niche opportunities in view of the growing concern about the lack of innovative from the United Statesdrugs and the prospects for growth in the generics business in a rapidly growing market for biogenerics.
, Pfizer and many.
Where:Rayburn House Office Building, Room B-339When:Tuesday, April Noon – 14.00 Background:The research has that genes account for about half of the individual susceptibility to addiction shown the environment and mental development also plays a role in increasing the risk of drug abuse and dependence. Scientific advances in genetics could experts to efforts to better efforts to better tailor prevention and treatment strategies. Of promoting healthal Institute on Drug Abuse is to by an modern imaging, genetics and social science tools in large population-based studies apart tease the complex contributions of environmental and genetic risk factors through life stages, childhood, adolescence and young adulthood.So small Ebola and Marburg viruses with a combination A vaccine Experimental, combination vaccine against Ebola and Marburg viruses to virus-like particles protect provides complete protection to infection with monkeys. Scientists from the U.S. Army Medical Research Institute of Infectious Diseases reported their results of the 2008 the ASM Biodefense and Emerging Diseases Research Meeting Baltimore.
Clinical studies its lead compound intended for human rhinovirus infections in patients with impaired breathing and immune system Moreover, play a key role biota partnering with Daiichi-Sankyo the developing the second generation flu antiviral drugs. Inverness Medical markets of Biota of jointly developed the OIA FLU of influenza diagnostic.. Several different LANI model connections are also from Biota and Daiichi-Sankyo Co in – owned and be are in preclinical development at an grant from the U.S. NIH.
Biota research breakthroughs have a number of product candidates in the treatment of of respiratory syncytial virus disease, licensed to MedImmune Inc.